Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Exelixis Inc. Common Stock (EXEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Exelixis Inc. Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B), while Exelixis Inc. Common Stock trades at $58.58 (market cap $14.48B). The key difference: Exelixis Inc. Common Stock is far larger — about 3.1× Definium Therapeutics Inc. Common Shares's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Exelixis Inc. Common Stock for 0 Days on average.
| DFTX | EXEL | |
|---|---|---|
Market Cap | $4.71B | $14.48B |
Volume | 1,966,636 | 2,374,774 |
Sector | Health | Health |
52-Week High | $48.45 | $59.13 |
52-Week Low | $10.68 | $34.54 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.67B | $13.81B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →
